Luyan Pharma Co Ltd
Luyan Pharma Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China. The company distributes medicines, Chinese herbal medicines, medical devices, and others; and provides medical care, elderly care, and wellness services. It also operates pharmaceutical retail chains. The company was formerly known as Luyan (Fujian… Read more
Luyan Pharma Co Ltd (002788) - Net Assets
Latest net assets as of September 2025: CN¥3.26 Billion CNY
Based on the latest financial reports, Luyan Pharma Co Ltd (002788) has net assets worth CN¥3.26 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.04 Billion) and total liabilities (CN¥9.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.26 Billion |
| % of Total Assets | 25.02% |
| Annual Growth Rate | 18.4% |
| 5-Year Change | 32.65% |
| 10-Year Change | 327.87% |
| Growth Volatility | 20.14 |
Luyan Pharma Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Luyan Pharma Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Luyan Pharma Co Ltd (2011–2024)
The table below shows the annual net assets of Luyan Pharma Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.19 Billion | +7.22% |
| 2023-12-31 | CN¥2.98 Billion | +6.68% |
| 2022-12-31 | CN¥2.79 Billion | +9.00% |
| 2021-12-31 | CN¥2.56 Billion | +6.40% |
| 2020-12-31 | CN¥2.41 Billion | +27.45% |
| 2019-12-31 | CN¥1.89 Billion | +14.18% |
| 2018-12-31 | CN¥1.65 Billion | +5.57% |
| 2017-12-31 | CN¥1.57 Billion | +13.65% |
| 2016-12-31 | CN¥1.38 Billion | +84.74% |
| 2015-12-31 | CN¥746.00 Million | +14.89% |
| 2014-12-31 | CN¥649.30 Million | +16.39% |
| 2013-12-31 | CN¥557.87 Million | +24.48% |
| 2012-12-31 | CN¥448.15 Million | +26.27% |
| 2011-12-31 | CN¥354.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Luyan Pharma Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1721.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.95 Billion | 61.75% |
| Common Stock | CN¥388.52 Million | 12.29% |
| Other Comprehensive Income | CN¥206.52 Million | 6.53% |
| Other Components | CN¥614.54 Million | 19.43% |
| Total Equity | CN¥3.16 Billion | 100.00% |
Luyan Pharma Co Ltd Competitors by Market Cap
The table below lists competitors of Luyan Pharma Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SIPEF SA (POST SPLIT)
F:BZ3
|
$450.18 Million |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
$450.20 Million |
|
Investis Holding SA
SW:IREN
|
$450.20 Million |
|
DOM DEVELOPMENT SE.A.ZY 1
F:6WV
|
$450.29 Million |
|
Chongqing Shunbo Aluminum Co Ltd
SHE:002996
|
$449.92 Million |
|
The Hongkong and Shanghai Hotels Limited
F:HSG
|
$449.80 Million |
|
Vishay Precision Group Inc
NYSE:VPG
|
$449.70 Million |
|
Internacional de Cerámica S.A.B. de C.V
MX:CERAMICB
|
$449.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Luyan Pharma Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,946,258,377 to 3,162,233,658, a change of 215,975,281 (7.3%).
- Net income of 345,644,716 contributed positively to equity growth.
- Dividend payments of 323,826,593 reduced retained earnings.
- Other comprehensive income increased equity by 397,855.
- Other factors increased equity by 193,759,303.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥345.64 Million | +10.93% |
| Dividends Paid | CN¥323.83 Million | -10.24% |
| Other Comprehensive Income | CN¥397.86K | +0.01% |
| Other Changes | CN¥193.76 Million | +6.13% |
| Total Change | CN¥- | 7.33% |
Book Value vs Market Value Analysis
This analysis compares Luyan Pharma Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.44x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.36 | CN¥14.21 | x |
| 2012-12-31 | CN¥1.69 | CN¥14.21 | x |
| 2013-12-31 | CN¥2.11 | CN¥14.21 | x |
| 2014-12-31 | CN¥2.45 | CN¥14.21 | x |
| 2015-12-31 | CN¥2.80 | CN¥14.21 | x |
| 2016-12-31 | CN¥4.11 | CN¥14.21 | x |
| 2017-12-31 | CN¥4.20 | CN¥14.21 | x |
| 2018-12-31 | CN¥4.46 | CN¥14.21 | x |
| 2019-12-31 | CN¥5.10 | CN¥14.21 | x |
| 2020-12-31 | CN¥6.02 | CN¥14.21 | x |
| 2021-12-31 | CN¥6.41 | CN¥14.21 | x |
| 2022-12-31 | CN¥7.00 | CN¥14.21 | x |
| 2023-12-31 | CN¥7.58 | CN¥14.21 | x |
| 2024-12-31 | CN¥8.14 | CN¥14.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Luyan Pharma Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.93%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.69%
- • Asset Turnover: 1.62x
- • Equity Multiplier: 4.00x
- Recent ROE (10.93%) is below the historical average (13.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 17.97% | 2.16% | 2.22x | 3.75x | CN¥28.22 Million |
| 2012 | 20.31% | 1.93% | 2.11x | 4.99x | CN¥45.94 Million |
| 2013 | 19.55% | 1.96% | 1.95x | 5.10x | CN¥52.90 Million |
| 2014 | 17.02% | 1.74% | 1.90x | 5.16x | CN¥45.10 Million |
| 2015 | 15.39% | 1.71% | 1.93x | 4.65x | CN¥39.72 Million |
| 2016 | 8.43% | 1.65% | 1.99x | 2.56x | CN¥-21.50 Million |
| 2017 | 8.86% | 1.57% | 1.62x | 3.48x | CN¥-16.79 Million |
| 2018 | 11.49% | 1.57% | 1.89x | 3.87x | CN¥23.39 Million |
| 2019 | 14.28% | 1.70% | 1.99x | 4.21x | CN¥76.72 Million |
| 2020 | 11.39% | 1.72% | 1.84x | 3.60x | CN¥32.58 Million |
| 2021 | 12.28% | 1.74% | 1.76x | 4.01x | CN¥56.70 Million |
| 2022 | 12.69% | 1.77% | 1.65x | 4.33x | CN¥73.07 Million |
| 2023 | 12.34% | 1.83% | 1.68x | 4.00x | CN¥68.90 Million |
| 2024 | 10.93% | 1.69% | 1.62x | 4.00x | CN¥29.42 Million |
Industry Comparison
This section compares Luyan Pharma Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,196,555,023
- Average return on equity (ROE) among peers: 8.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Luyan Pharma Co Ltd (002788) | CN¥3.26 Billion | 17.97% | 3.00x | $450.11 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $4.92 Billion | 13.40% | 1.65x | $437.62 Million |
| Yunnan Hongxiang Yixintang (002727) | $497.43 Million | 20.70% | 1.22x | $545.21 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $18.23 Million |
| Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) | $856.04 Million | 6.95% | 0.97x | $170.91 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $188.58 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.78 Billion | 1.93% | 1.96x | $174.48 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $1.98 Billion | 5.80% | 1.33x | $323.73 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $736.00 Million | 6.25% | 0.61x | $180.65 Million |
| Laobaixing Pharmacy (603883) | $7.10 Billion | 11.06% | 2.01x | $739.96 Million |